Merck's PCSK9 pill holds 'significant advantage' with injectable-like cholesterol reductions: analysts - Fierce Biotech

In late-stage studies, Merck & Co.’s PCSK9-targeted pill achieved low-density lipoprotein cholesterol (LDL-C) reductions similar to those observed with existing injectables. | Merck & Co.’s PCSK9-targeted pill achieved low-density lipoprotein cholesterol (LDL…